Scheduled maintenance until 6:00 AM EST.
Developing Regulated Therapeutic and Diagnostic Solutions for Patients Affected by Opioid and/or Stimulants use Disorders (OUD/StUD) (R41/R42 Clinical Trial Optional)
ID: 347599Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Award Range

$0 - $300K

Eligible Applicants

Small Businesses

Funding Category

Health

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes
Timeline
  1. 1
    Forecast Posted Not available
  2. 2
    Forecast Due Not available
  3. 3
    Posted Apr 18, 2023 12:00 AM
  4. 4
    Due Feb 14, 2025 12:00 AM
Description

The National Institutes of Health (NIH) has posted a grant opportunity titled "Developing Regulated Therapeutic and Diagnostic Solutions for Patients Affected by Opioid and/or Stimulants use Disorders (OUD/StUD) (R41/R42 Clinical Trial Optional)". This grant aims to encourage Small Business Technology Transfer (STTR) grant applications from small business concerns (SBCs) to develop novel, evidence-based, FDA-regulated medical products for patients suffering from opioid use disorders (OUD) and/or stimulant use disorders (StUD). The grant focuses on two scientific areas: pharmacotherapeutics (small molecules and biologics) and medical therapeutic and diagnostic devices, including software as a medical device. The goal is to contribute to the effort against the national opioid and psychostimulant emergency and provide new medical products for individuals, families, and communities affected by this crisis. Small business companies that have developed or are developing FDA-regulated products for different indications and are interested in demonstrating their potential application in the OUD/StUD space are encouraged to apply. The grant does not require cost sharing or matching and is open to small businesses. Non-domestic entities and components are not eligible to apply. The closing date for applications is February 14, 2025. For more information and to apply, visit the grant opportunity website. For inquiries, contact NIH Grants Information at grantsinfo@nih.gov.

Point(s) of Contact
Files
Title
Posted
Similar Opportunities
Developing Regulated Therapeutic and Diagnostic Solutions for Patients Affected by Opioid and/or Stimulants use Disorders (OUD/StUD) (R43/R44 - Clinical Trial Optional)
National Institutes of Health
The National Institutes of Health (NIH) is offering a grant opportunity titled "Developing Regulated Therapeutic and Diagnostic Solutions for Patients Affected by Opioid and/or Stimulants use Disorders (OUD/StUD) (R43/R44 - Clinical Trial Optional)". This grant aims to support small businesses in developing novel, evidence-based, FDA-regulated medical products to address the needs of patients suffering from opioid use disorders (OUD) and stimulant use disorders (StUD). The grant encourages research projects focused on commercialization in two scientific areas: pharmacotherapeutics (small molecules and biologics) and medical therapeutic and diagnostic devices, including software as a medical device. The goal is to contribute to the national effort against the opioid and psychostimulant crisis by offering new medical products for individuals, families, and communities affected by these disorders. Small businesses are eligible to apply, and the grant does not require cost sharing or matching. The deadline for applications is February 14, 2025. For more information and to apply, visit the following link: [http://grants.nih.gov/grants/guide/rfa-files/RFA-DA-23-021.html](http://grants.nih.gov/grants/guide/rfa-files/RFA-DA-23-021.html). For any inquiries, contact the NIH OER Webmaster at OERWebmaster03@od.nih.gov.
Seeking Products to Address Social Needs impacting Substance Use Disorders (SUD) (R41/R42 Clinical Trial Optional)
National Institutes of Health
The National Institutes of Health is seeking products to address social needs impacting Substance Use Disorders (SUD) through a Grant opportunity. This funding opportunity aims to support small business concerns (SBCs) in developing technologies for commercialization that can address health-related social needs affecting SUD, excluding alcohol use disorder. The grant does not require cost sharing or matching requirements. The eligible applicants for this grant are small businesses. Non-domestic entities and non-U.S. components of U.S. organizations are not eligible to apply. However, foreign components, as defined in the NIH Grants Policy Statement, may be allowed. The closing date for this grant opportunity is March 13, 2026. The award ceiling for this grant is $295,924. For more information and to apply, interested parties can visit the following website: [http://grants.nih.gov/grants/guide/rfa-files/RFA-DA-25-047.html](http://grants.nih.gov/grants/guide/rfa-files/RFA-DA-25-047.html). For any inquiries, please contact NIH Grants Information at grantsinfo@nih.gov.
Solutions to enable diagnosis and treatment of adverse health consequences of non-disordered drug use (R41/R42 - Clinical Trial Optional)
National Institutes of Health
The National Institutes of Health is offering a grant opportunity titled "Solutions to enable diagnosis and treatment of adverse health consequences of non-disordered drug use (R41/R42 - Clinical Trial Optional)". This grant aims to develop innovative solutions to improve health outcomes and reduce the impact of adverse health consequences in individuals who use drugs. The solutions should be accessible and affordable, with a focus on mobile community-based care systems to reach vulnerable and underserved populations with limited engagement in conventional healthcare services. The grant is open to small businesses, and the deadline for application submission is December 2, 2024. For more information and to apply, please visit the following link: [http://grants.nih.gov/grants/guide/rfa-files/RFA-DA-25-049.html](http://grants.nih.gov/grants/guide/rfa-files/RFA-DA-25-049.html).
Seeking Products to Address Social Needs impacting Substance Use Disorders (SUD) (R43/R44 Clinical Trial Optional)
National Institutes of Health
The National Institutes of Health is seeking products to address social needs impacting Substance Use Disorders (SUD) through a Grant opportunity. This funding opportunity aims to support small business concerns (SBCs) in developing technologies for commercialization that can address health-related social needs affecting SUD, excluding alcohol use disorder. The grant does not require cost sharing or matching requirements. The eligible applicants for this grant are small businesses. Non-domestic entities and non-U.S. components of U.S. organizations are not eligible to apply, although foreign components may be allowed. The maximum award ceiling for this grant is $295,924. The closing date for applications is March 13, 2026. For more information and to apply, please visit the following link: [http://grants.nih.gov/grants/guide/rfa-files/RFA-DA-25-048.html](http://grants.nih.gov/grants/guide/rfa-files/RFA-DA-25-048.html). For any inquiries, please contact NIH Grants Information at grantsinfo@nih.gov.
Development of Medications to Prevent and Treat Opioid and/or Stimulant Use Disorders and Overdose (UG3/UH3 - Clinical Trial Optional)
National Institutes of Health
The National Institutes of Health is offering a federal grant opportunity titled "Development of Medications to Prevent and Treat Opioid and/or Stimulant Use Disorders and Overdose (UG3/UH3 - Clinical Trial Optional)". This grant aims to support the discovery and development of medications to prevent and treat opioid and/or psychostimulant use disorders and overdose. The funding instrument type for this opportunity is a Cooperative Agreement. The grant falls under the category of funding activity related to health. The grant does not require cost sharing or matching. The eligible applicants for this grant include various institutions and organizations such as Alaska Native and Native Hawaiian Serving Institutions, Asian American Native American Pacific Islander Serving Institutions (AANAPISISs), Eligible Agencies of the Federal Government, Faith-based or Community-based Organizations, Hispanic-serving Institutions, Historically Black Colleges and Universities (HBCUs), Indian/Native American Tribal Governments (Other than Federally Recognized), Non-domestic (non-U.S.) Entities (Foreign Organizations), Regional Organizations, Tribally Controlled Colleges and Universities (TCCUs), and U.S. Territory or Possession. The purpose of this grant is to support the discovery and development of medications that can prevent and treat opioid and/or psychostimulant use disorders and overdose. The grant involves two phases, UG3 and UH3. The UG3 phase provides support for a project with specific milestones to be accomplished within a 2-year period. The UH3 phase provides funding for 3 years to a project that successfully completes the milestones set in the UG3 phase. Projects that meet their milestones in the UG3 phase will be considered for transition to the UH3 phase. The grant encourages applications that include preclinical or clinical research studies with high impact and quick results to advance medications closer to FDA approval for the prevention and treatment of opioid use disorders and overdose. The compounds to be evaluated can be small molecules or biologics, and they can be tested in pre-clinical models or for the clinical manifestations of opioid use disorders such as withdrawal, craving, relapse, or overdose. The grant also supports the development of new chemical entities, new formulations of marketed medications available for other indications, or combinations of medications that hold promise for the treatment of opioid use disorders and overdose. The goal of this grant is to fast-track the discovery and development of medications to prevent and treat opioid use disorders or opioid overdose and advance them in the FDA's drug development approval pipeline. For more information and to apply for this grant opportunity, please visit the following link: [Development of Medications to Prevent and Treat Opioid and/or Stimulant Use Disorders and Overdose (UG3/UH3 - Clinical Trial Optional)](http://grants.nih.gov/grants/guide/pa-files/PAR-22-200.html). If you have any inquiries, you can contact NIH Grants Information at grantsinfo@nih.gov.